Lincoln Capital Corp decreased its position in Keryx Biopharmaceuticals (NASDAQ:KERX) by 43.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 37,280 shares of the biopharmaceutical company’s stock after selling 28,520 shares during the quarter. Lincoln Capital Corp’s holdings in Keryx Biopharmaceuticals were worth $127,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in shares of Keryx Biopharmaceuticals in the first quarter worth about $201,000. Shufro Rose & Co. LLC raised its stake in shares of Keryx Biopharmaceuticals by 26.1% in the second quarter. Shufro Rose & Co. LLC now owns 91,800 shares of the biopharmaceutical company’s stock worth $345,000 after buying an additional 19,000 shares during the period. SG Americas Securities LLC bought a new position in shares of Keryx Biopharmaceuticals in the second quarter worth about $399,000. Swiss National Bank raised its stake in shares of Keryx Biopharmaceuticals by 13.0% in the first quarter. Swiss National Bank now owns 160,600 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 18,500 shares during the period. Finally, UBS Group AG raised its stake in shares of Keryx Biopharmaceuticals by 126.0% in the first quarter. UBS Group AG now owns 231,934 shares of the biopharmaceutical company’s stock worth $949,000 after buying an additional 129,296 shares during the period. 59.52% of the stock is currently owned by institutional investors.
NASDAQ:KERX opened at $3.16 on Wednesday. The company has a debt-to-equity ratio of -3.16, a current ratio of 2.28 and a quick ratio of 1.40. Keryx Biopharmaceuticals has a 12-month low of $2.78 and a 12-month high of $8.07. The stock has a market cap of $409.56 million, a P/E ratio of -3.59 and a beta of 2.44.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). As a group, research analysts anticipate that Keryx Biopharmaceuticals will post -0.61 EPS for the current year.
Several research analysts have recently commented on KERX shares. HC Wainwright set a $9.00 price objective on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 23rd. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research report on Tuesday, July 10th. Stifel Nicolaus reiterated a “hold” rating and set a $5.00 target price on shares of Keryx Biopharmaceuticals in a research report on Monday, June 25th. ValuEngine upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 21st. Finally, BidaskClub upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $6.25.
Keryx Biopharmaceuticals Profile
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Further Reading: How Do Tariffs Affect Trade Balances?